Clinical Trials Browser

Phase 1 × Active not recruiting × EGFR Positive Non-small Cell Lung Cancer × Clear all

NCT04001777 2025-10-01

A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients

Phase 1 Active not recruiting

EGFR Positive Non-small Cell Lung Cancer